A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids

Allergan

Status: Completed

Conditions: Leiomyoma

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02580578

CMO-CAN-WH-0412

Details and patient eligibility

About

This study will characterize the treatments and outcomes associated with different uterine fibroid treatments in Canada, to understand patients' preferences and satisfaction with different medical and procedural interventions. The study will also assess the effectiveness of ulipristal acetate (Fibristal®) in controlling bleeding, reducing fibroid volume and symptoms, and improvement in patient's quality of life.

Enrollment: 1,500 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Pre-menopausal adult women with confirmed diagnosis and symptoms associated with uterine fibroids who are initiating treatment.

Exclusion criteria

-Significant pelvic pathology not associated with uterine fibroids.

Trial design

1,500 participants in 1 patient group

All Participants

Description:

Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.

Treatment:

Other: No Intervention